# A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

> **NCT03070964** · PHASE2 · TERMINATED · sponsor: **PharmaMar** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** plitidepsin

## Key facts

- **NCT ID:** NCT03070964
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-25
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The main reason that motivated the study termination was the slow recruitment of the trial.
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070964, "A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03070964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*